Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis

Immune Network
Se Jin OhTae Woo Kim

Abstract

Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's potential to revolutionize cancer treatment, the presence of immunotherapeutic-resistant tumor cells in many patients present a challenge and limitation to these immunotherapies. These cells not only indicate immunotherapeutic resistance, but also show multi-modal resistance to conventional therapies, abnormal metabolism, stemness, and metastasis. How can immunotherapeutic-resistant tumor cells render multi-malignant phenotypes? We reasoned that the immune-refractory phenotype could be associated with multi-malignant phenotypes and that these phenotypes are linked together by a factor that acts as the master regulator. In this review, we discussed the role of the embryonic transcription factor NANOG as a crucial master regulator we named "common factor" in multi-malignant phenotypes and presented strategies to overcome multi-malignancy in immunotherapeutic-resistant cancer by restraining the NANOG-mediated multi-malignant signaling axis. Strategies that blunt the NANOG axis could improve the clinical management of ...Continue Reading

References

Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shih-Hwa ChiouJeng-Fan Lo
Jul 11, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Benedetta BussolatiGiovanni Camussi
May 23, 2009·Science·Matthew G Vander HeidenCraig B Thompson
Oct 3, 2009·Annals of the New York Academy of Sciences·Tobias Schatton, Markus H Frank
Jan 7, 2010·The Journal of Clinical Investigation·Natasha Y FrankMarkus H Frank
May 15, 2010·Nature Reviews. Drug Discovery·Simone FuldaGuido Kroemer
Feb 24, 2011·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Lo-Lin TsaiMing-Yung Chou
Apr 6, 2011·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Xi ZhouSheng-Rong Xu
Apr 25, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Takuya NagataKazuhiro Tsukada
May 9, 2012·Digestive Diseases and Sciences·Feng XuChangjun Jia
Oct 25, 2012·The Journal of Clinical Investigation·Kyung Hee NohTae Woo Kim
Oct 26, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Maria LeeYoung Tae Kim
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Nov 8, 2013·Immune Network·Yeong-Min ParkHee Dong Han
Jun 7, 2014·Molecular Cell·Hariharan EaswaranStephen B Baylin
Sep 25, 2014·BMB Reports·Kwon-Ho SongTae Woo Kim
Jan 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Young-Ho LeeTae Woo Kim
Apr 23, 2015·Clinical & Experimental Metastasis·Hyo-Jung LeeTae Woo Kim
Sep 2, 2015·The Journal of Clinical Investigation·Yiping Yang
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 19, 2016·Trends in Biochemical Sciences·Maria V Liberti, Jason W Locasale
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Sep 9, 2017·Experimental & Molecular Medicine·Han Sol JangTae Woo Kim
Aug 21, 2018·The Journal of Clinical Investigation·Kwon-Ho SongTae Woo Kim

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.